Immunogen (IMGN) Prices Upsized 11.64M Share Offering at $6.60/sh

Jefferies Upgrades Immunogen Inc. (IMGN) to Buy

Jefferies analyst Kelly Shi upgraded Immunogen Inc. (NASDAQ: IMGN) from Hold to Buy with a price target of $12.00 (from $7.00).

For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.

Shares of Immunogen Inc. closed at $6.45 yesterday.

Immunogen (IMGN) to Offer $175M in Common Stock

ImmunoGen Inc. (Nasdaq:... More

Immunogen Inc. (IMGN) PT Raised to $7 at SVB Leerink, Following Clinical Business Update

SVB Leerink analyst Jonathan Chang raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $7.00 (from $5.00) while maintaining a Market Perform rating.

Increasing unusual option volume: IMGN EWG KRYS CHS CERN VIR EVC BZUN

Increasing unusual option volume: IMGN EWG KRYS CHS CERN VIR EVC BZUN

Pre-Open Stock Movers 11/30: (CPIX) (IMGN) (VIR) Higher; (JKS) (LIZI) (SEDG) Lower (more...)

Pre-Open Movers

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) 129% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever may now be administered just prior to surgery to enable patients to wake up from their procedure in significantly less pain.

ImmunoGen Inc. (Nasdaq: IMGN) 45.5% HIGHER; announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy... More

Immunogen (IMGN) Shares Up 40%, Following Positive SORAYA Trial Results

Immunogen (NASDAQ: IMGN) shares are gaining nearly 40% in pre-market on heavy volume, following positive results from the company's SORAYA clinical trial.

Immunogen (IMGN) Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FR)-high platinum-resistant ovarian cancer who have been previously treated with Avastin® (bevacizumab).

... More